Appearance of lentigines in psoriasis patients treated with apremilast

To the Editor: The development of lentigines in areas previously affected by psoriasis plaques is a rare event mainly reported after phototherapy. Several cases of lentigines appearing in resolving psoriatic plaques during or after treatment with anti-tumor necrosis factor (TNF) or anti-interleukin (IL)-12/IL-23 drugs have been reported but they remain anecdotal.1-3 Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that was approved by the US Food and Drug Administration (FDA) in 2014 and by the European Medical Agency in 2015 for the treatment of psoriasis and psoriatic arthritis.

http://ift.tt/2fN8uId